|
Humanizovana monoklonalna antitela ("-zu-") |
|
| "-tuzu-" (tumor) |
Afutuzumab, Alemtuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Dacetuzumab, Elotuzumab†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab§, Milatuzumab, Nimotuzumab, Oportuzumab monatox, Pertuzumab, Sibrotuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab
|
|
| "-lizu-" (imunski sistem) |
imunosupresivni: Aselizumab, Apolizumab, Benralizumab†, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, PRO 140†, Reslizumab, Rontalizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412§
non-imunosupresivni: Ibalizumab†
|
|
| "-bazu-" (bakterijski) |
|
|
| "-cizu-" (kardiovaskularni) |
|
|
| "-nezu-"/"-neuzu-" (nervni sistem) |
|
|
| "-toksazu-" (toksin kao meta) |
|
|
| "-vizu-" (viralni) |
|
|
| "-kizu-" (interleukin kao meta) |
|
|
| "-anibizu-" (inhibitor angiogeneze) |
|
|
| †U kliničkim ispitivanjima. §Nije bio u prodaji. |
|
